ScreenPoint Medical's Transpara AI Chosen for $16M Breast Cancer Screening Trial
ScreenPoint Medical has announced that its Transpara breast imaging AI solution will be used in the PRISM Trial, a significant randomized controlled trial in the United States. Announced in a press release, the trial is funded by a $16 million award from the Patient-Centered Outcomes Research Institute (PCORI) and aims to assess the effectiveness of AI in breast cancer screening.
The PRISM Trial, led by UCLA and UC Davis, will explore whether AI can assist radiologists in detecting breast cancer earlier, improving mammography accuracy, and reducing unnecessary patient callbacks. The study will involve hundreds of thousands of mammograms interpreted at leading academic medical centers, including UCLA, UC Davis, and others.
ScreenPoint Medical's Transpara Detection software will be integrated into the clinical workflow using the Aidoc aiOS platform, supporting the trial's objectives to enhance early breast cancer detection and improve patient-centered care systems.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 19 Knit Health raises $35 million to roll out its healthcare world model Nov 19 Banner Health invests in Layer Health and moves its clinical registries onto its AI platform Nov 19 Half of Koreans who changed medication on AI advice had side effects, survey finds Nov 19 Isomorphic Labs and MSD team up to design cancer drugs with AI Nov 19 Boltz raises $110 million to build AI models for drug designMore from Funding
Nov 20 hackajob raises $10 million to expand Archer, its AI recruiting agent Nov 20 Protesters rally against Anthropic in New York and San Francisco on its stock market debut Nov 19 Anthropic's IPO could channel about $156 billion to charity, TechCrunch estimates Nov 19 Sierra reportedly in talks to raise at a $30 billion valuation Nov 19 Everful raises $48.5 million to build AI infrastructure for global commerceLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Cancer researchers start testing AURORA AI co-scientists built at Harvard
Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans
Tesorai raises $5.3 million to make raw lab data searchable with AI
Switchpoint Bio raises $5.3 million for AI epigenomics platform
RADPAIR builds its AI radiology reporting into Novarad's NovaPACS imaging platform
Daily AI Brief: the AI news that matters, in your inbox.